NovoCure (NVCR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Core Insights - NovoCure reported revenue of $154.99 million for Q1 2025, marking an 11.9% year-over-year increase and exceeding the Zacks Consensus Estimate of $147.57 million by 5.03% [1] - The company posted an EPS of -$0.31, an improvement from -$0.36 a year ago, and surpassed the consensus EPS estimate of -$0.47 by 34.04% [1] Revenue Breakdown - Greater China net revenues reached $4.62 million, exceeding the average estimate of $3.79 million from two analysts [4] - Total net revenues from international markets amounted to $57.22 million, surpassing the average estimate of $53.77 million from two analysts [4] - Japan's net revenues were reported at $8.71 million, slightly above the average estimate of $8.70 million from two analysts [4] - United States net revenues totaled $93.15 million, exceeding the average estimate of $90.92 million from two analysts [4] Stock Performance - NovoCure's shares have returned -3.6% over the past month, compared to a -5.1% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]